Diabetic Foot Ulcer (DFU) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Diabetic Foot Ulcer (DFU) Market Outlook

Thelansis’s “Diabetic Foot Ulcer (DFU) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Foot Ulcer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Foot Ulcer (DFU) Overview

Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus and often lead to lower extremity amputation. The most common causes of DFUs are neuropathy, deformity, trauma, high plantar pressures, and peripheral arterial disease. DFUs are classified into different grades using the Wagner classification system, with Grade 0 being the least severe and Grade V being the most severe. Another classification system, the PEDIS system, considers perfusion, extent/size, depth/tissue loss, infection, and sensation. The PEDIS classification is highly relevant to the development of DFUs. The most common laboratory investigations done during the evaluation of a DFU include fasting blood sugar, glycated hemoglobin levels, complete metabolic panel, complete blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). The prognosis for DFUs is good if they are identified early and treated promptly. However, delays in care can lead to severe complications, such as amputation. Patients with chronic DFUs have a high risk of rehospitalization and prolonged hospitalization. The most feared complication of a DFU is amputation of the extremity. Other complications include foot gangrene, osteomyelitis, permanent deformity, and sepsis.

• The prevalence of DFUs in the United States is 15-20%, and the risk of amputation is 15-46 times higher for people with diabetes than those without diabetes.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: